{"id":34604,"date":"2025-06-03T17:21:00","date_gmt":"2025-06-03T09:21:00","guid":{"rendered":"https:\/\/flcube.com\/?p=34604"},"modified":"2025-06-03T17:21:01","modified_gmt":"2025-06-03T09:21:01","slug":"neowise-biotech-licenses-tcr-molecule-to-beone-medicines-for-next-gen-cell-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34604","title":{"rendered":"Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy"},"content":{"rendered":"\n

Suzhou-based Neowise Biotechnology, a specialist in T Cell Receptor (TCR)-based therapies for solid tumors, announced a non-exclusive license agreement with BeOne Medicines Ltd. (NASDAQ: ONC<\/a>, HKG: 6160<\/a>, SHA: 688235<\/a>). This agreement grants BeOne access to Neowise\u2019s antigen-specific TCR molecule, which is expected to facilitate the development of next-generation universal cell therapies based on BeOne’s iPSC platform.<\/p>\n\n\n\n

Financial Terms and Collaboration Benefits<\/strong>
Under the terms of the agreement, Neowise will receive an undisclosed upfront payment and is eligible for development, regulatory, and commercial milestone payments, as well as sales commission. This partnership highlights the potential of Neowise’s TCR molecule to enhance BeOne’s cell therapy pipeline and drive innovation in the treatment of solid tumors.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Suzhou-based Neowise Biotechnology, a specialist in T Cell Receptor (TCR)-based therapies for solid tumors, announced…<\/p>\n","protected":false},"author":1,"featured_media":34605,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[185,2092,30,847,3046,3075,848],"class_list":["post-34604","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-beigene","tag-beone-medicines","tag-biotech","tag-hkg-6160","tag-nasdaq-onc","tag-neowise-biotechnology","tag-sha-688235"],"yoast_head":"\nNeowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou-based Neowise Biotechnology, a specialist in T Cell Receptor (TCR)-based therapies for solid tumors, announced a non-exclusive license agreement with BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235). This agreement grants BeOne access to Neowise\u2019s antigen-specific TCR molecule, which is expected to facilitate the development of next-generation universal cell therapies based on BeOne's iPSC platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34604\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy\" \/>\n<meta property=\"og:description\" content=\"Suzhou-based Neowise Biotechnology, a specialist in T Cell Receptor (TCR)-based therapies for solid tumors, announced a non-exclusive license agreement with BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235). This agreement grants BeOne access to Neowise\u2019s antigen-specific TCR molecule, which is expected to facilitate the development of next-generation universal cell therapies based on BeOne's iPSC platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34604\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-03T09:21:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-03T09:21:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0309.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34604#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34604\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy\",\"datePublished\":\"2025-06-03T09:21:00+00:00\",\"dateModified\":\"2025-06-03T09:21:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34604\"},\"wordCount\":132,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34604#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0309.webp\",\"keywords\":[\"BeiGene\",\"BeOne Medicines\",\"Biotech\",\"HKG: 6160\",\"NASDAQ: ONC\",\"Neowise Biotechnology\",\"SHA: 688235\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34604#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34604\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34604\",\"name\":\"Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34604#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34604#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0309.webp\",\"datePublished\":\"2025-06-03T09:21:00+00:00\",\"dateModified\":\"2025-06-03T09:21:01+00:00\",\"description\":\"Suzhou-based Neowise Biotechnology, a specialist in T Cell Receptor (TCR)-based therapies for solid tumors, announced a non-exclusive license agreement with BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235). This agreement grants BeOne access to Neowise\u2019s antigen-specific TCR molecule, which is expected to facilitate the development of next-generation universal cell therapies based on BeOne's iPSC platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34604#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34604\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34604#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0309.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0309.webp\",\"width\":1080,\"height\":608,\"caption\":\"Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34604#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy - Insight, China's Pharmaceutical Industry","description":"Suzhou-based Neowise Biotechnology, a specialist in T Cell Receptor (TCR)-based therapies for solid tumors, announced a non-exclusive license agreement with BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235). This agreement grants BeOne access to Neowise\u2019s antigen-specific TCR molecule, which is expected to facilitate the development of next-generation universal cell therapies based on BeOne's iPSC platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34604","og_locale":"en_US","og_type":"article","og_title":"Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy","og_description":"Suzhou-based Neowise Biotechnology, a specialist in T Cell Receptor (TCR)-based therapies for solid tumors, announced a non-exclusive license agreement with BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235). This agreement grants BeOne access to Neowise\u2019s antigen-specific TCR molecule, which is expected to facilitate the development of next-generation universal cell therapies based on BeOne's iPSC platform.","og_url":"https:\/\/flcube.com\/?p=34604","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-03T09:21:00+00:00","article_modified_time":"2025-06-03T09:21:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0309.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34604#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34604"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy","datePublished":"2025-06-03T09:21:00+00:00","dateModified":"2025-06-03T09:21:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34604"},"wordCount":132,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34604#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0309.webp","keywords":["BeiGene","BeOne Medicines","Biotech","HKG: 6160","NASDAQ: ONC","Neowise Biotechnology","SHA: 688235"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34604#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34604","url":"https:\/\/flcube.com\/?p=34604","name":"Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34604#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34604#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0309.webp","datePublished":"2025-06-03T09:21:00+00:00","dateModified":"2025-06-03T09:21:01+00:00","description":"Suzhou-based Neowise Biotechnology, a specialist in T Cell Receptor (TCR)-based therapies for solid tumors, announced a non-exclusive license agreement with BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235). This agreement grants BeOne access to Neowise\u2019s antigen-specific TCR molecule, which is expected to facilitate the development of next-generation universal cell therapies based on BeOne's iPSC platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34604#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34604"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34604#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0309.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0309.webp","width":1080,"height":608,"caption":"Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34604#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0309.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34604"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34604\/revisions"}],"predecessor-version":[{"id":34606,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34604\/revisions\/34606"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34605"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}